Ticker brief
GILD GILEAD SCIENCES INC
Consumer, Non-cyclical · Biotechnology
last close
$131.27
1 day
+4.2%
14 days
+6.1%
mkt cap
$163.0B
signals 14d
24
authors 14d
20
Sentiment — last 14 days
daily mean sentiment, 2026-06-22 → 2026-07-03 · now +0.38 (−1 bearish … +1 bullish)
Who spoke20
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @SwingTraderQ | B | +1.10 | 2 | +0.68 |
| @OzmosiHealth | C | · | 2 | +0.50 |
| @KunnuInvests | C | -0.40 | 2 | +0.67 |
| @Biotech2k1 | A | -0.03 | 2 | +0.40 |
| @BeatTheInsider | C | · | 1 | +0.15 |
| @capitol2iq | C | · | 1 | +0.15 |
| @MartyChargin | C | -0.72 | 1 | +0.50 |
| @fwpharma | B | +0.22 | 1 | +0.50 |
| @PersimmonTI | A | -0.32 | 1 | +0.00 |
| @WSJ | A | +0.51 | 1 | +0.50 |
| @tenet_research | C | -2.08 | 1 | +0.50 |
| @AlertsAndNews | C | +1.52 | 1 | +0.50 |
| @Volume_Stocks | C | -2.80 | 1 | +0.15 |
| @BrandonVanZee | C | +0.63 | 1 | +0.00 |
| @3PeaksTrading | B | -1.63 | 1 | +0.25 |
| @bioinvestor24 | A | +1.35 | 1 | +0.00 |
| @AryaFintech | C | +0.59 | 1 | +0.30 |
| @TradewithJade1 | C | -1.20 | 1 | +0.45 |
| @ScrooogeUncle | C | -2.04 | 1 | +0.20 |
| @AsafNaamani | C | -2.11 | 1 | +0.35 |
Recent signals24of 24 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-07-03 | @AsafNaamani | +0.35 | GILD daily chart is attempting a breakout. | — | tweet ↗ |
| 2026-07-03 | @Biotech2k1 | +0.45 | Thinking about rotating biotech weighting into GILD and REGN. — Author is considering rotating into big-cap biotech names. | — | tweet ↗ |
| 2026-07-03 | @Biotech2k1 | +0.35 | Names GILD, REGN and ALNY as rotation plays to examine. | — | tweet ↗ |
| 2026-07-02 | @ScrooogeUncle | +0.20 | Sees wobbly GILD swing setup with high volume and RSI, but waits for confirmation before long. | — | tweet ↗ |
| 2026-07-02 | @KunnuInvests | +0.65 | GILD reversed from $122, reclaimed 2W 20EMA and looks ready for next leg higher with XLV bullish. | — | tweet ↗ |
| 2026-07-02 | @SwingTraderQ | +0.60 | Will add GILD by the end of the day. — Explicit forward intent to add GILD by end of day. | — | tweet ↗ |
| 2026-07-01 | @TradewithJade1 | +0.45 | Says targets are juicy after checking GILD and INSM. | +4.2% | tweet ↗ |
| 2026-07-01 | @AryaFintech | +0.30 | Reports top 10 recommendation list returned 25.69% vs SPY 9.24%. | +4.2% | tweet ↗ |
| 2026-06-30 | @bioinvestor24 | +0.00 | Probably time to consider a long-term PFE position — Suggests a long-term Pfizer position amid potential shakeup or large deal. | +3.9% | tweet ↗ |
| 2026-06-30 | @3PeaksTrading | +0.25 | Reports fund buying March expiration calls across several stocks as second-half bets. | +3.9% | tweet ↗ |
| 2026-06-29 | @BrandonVanZee | +0.00 | Lists dividend pay-date stocks for 2026-06-29. | +3.9% | tweet ↗ |
| 2026-06-28 | @KunnuInvests | +0.70 | Looking to enter GILD soon after already entering LLY — Author says they entered LLY at $907 and are looking to enter GILD soon on a breakout. | +2.7% | tweet ↗ |
| 2026-06-28 | @Volume_Stocks | +0.15 | Discloses already-in TEM 7/17 55 calls and gives bullish thesis, raised guidance and targets. | +2.7% | tweet ↗ |
| 2026-06-24 | @AlertsAndNews | +0.50 | FDA approved Gilead's Trodelvy for first-line metastatic triple-negative breast cancer. | +4.9% | tweet ↗ |
| 2026-06-24 | @OzmosiHealth | +0.50 | FDA approves Trodelvy for first-line metastatic triple-negative breast cancer. | +4.9% | tweet ↗ |
| 2026-06-24 | @tenet_research | +0.50 | Gilead receives FDA approval for Trodelvy ADC in metastatic triple-negative breast cancer. | +4.9% | tweet ↗ |
| 2026-06-24 | @WSJ | +0.50 | AstraZeneca and Gilead won approvals for treatments of advanced breast cancer. | +4.9% | tweet ↗ |
| 2026-06-23 | @PersimmonTI | +0.00 | Long biotech framework around repeat surprise, valuation, M&A and disciplined humility. | +5.0% | tweet ↗ |
| 2026-06-23 | @fwpharma | +0.50 | EU clears Gilead Trodelvy for frontline TNBC while Datroway decision looms. | +5.0% | tweet ↗ |
| 2026-06-23 | @OzmosiHealth | +0.50 | European Commission approves Trodelvy first-line metastatic TNBC indication. | +5.0% | tweet ↗ |
| 2026-06-23 | @MartyChargin | +0.50 | European Commission grants marketing authorization for Gilead's Trodelvy use. | +5.0% | tweet ↗ |
| 2026-06-22 | @SwingTraderQ | +0.75 | States GILD is a $400 stock, implying strong upside target. | +5.1% | tweet ↗ |
| 2026-06-22 | @capitol2iq | +0.15 | Reports Rep sold COR on earnings day and bought GILD across two accounts. | +5.1% | tweet ↗ |
| 2026-06-22 | @BeatTheInsider | +0.15 | Political disclosure: Rep. Moskowitz bought GILD and sold COR in $2k-$30k ranges. | +5.1% | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.